2nd Annual Mercy Health Oncology Symposium
We’re a company that takes on the toughest health challenges. But we do more than treat diseases—we aim to make a remarkable impact on people’s lives. We are AbbVie, a highly focused research-driven biopharmaceutical company.
Our ~29,000 employees are scientists, researchers, communicators, manufacturing specialists and regulatory experts located around the globe. We come up with new approaches to addressing today’s health issues—from life-threatening illness to chronic conditions.
We target specific difficult-to-cure diseases where we can leverage our core R&D expertise to advance science. We’re constantly working to create solutions that go beyond treating the illness to have a positive impact on patients’ lives, on societies—and on science itself.
To learn more about AbbVie, stop by their exhibit table or visit them online.
Astellas Pharma US, Inc., is a U.S. affiliate of Tokyo-based Astellas Pharma Inc., with its headquarters located in Northbrook, Illinois. More than 3,000 Astellas employees are based in the United States. Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products.
Our commitment to changing tomorrow is measured not only by our focus on bringing innovative and effective new medicines to patients and physicians, but also by the importance we place on the impact we can make within the communities where we work and live. Astellas supports many causes and has created Changing Tomorrow Day, an annual, worldwide volunteer event, to demonstrate this commitment.
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines in Oncology and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries, and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca-us.com and follow us on Twitter @AstraZenecaUS.
We are a global, science-led, patient-focused pharmaceutical company. We are dedicated to transforming the future of healthcare by unlocking the power of what science can do for people, society and the planet.
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology; Cardiovascular, Renal & Metabolism; and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
Our mission is to build the first next-generation biotechnology company – one that expands the highest quality therapies to more people around the world – through courage, persistent innovation, and challenging the status quo.
Our values – patients first, bold ingenuity, collaborative spirit, and driving excellence- are the foundation of what we stand for.
We are driven by the power of change. We lead Change by: making life-saving medicines accessible to billions more patients around the world; challenging the status quo and pushing the boundaries to make the impossible, possible; removing systemic injustices and inequities; creating boundless opportunities for people to thrive; and having the transformative power to shift paradigms. At BeiGene, we believe Change is the Cure, and it begins with us!
Change is the Cure delivers in our mission and codifies the work we are doing to go beyond our life-saving medicines to meet the diverse needs of the global population – from patients and colleagues to investors and the communities in which we serve. Our business plays an important role in creating a more equitable and sustainable world.
We do this by focusing on:
Advancing Global Health
Empowering Our Colleagues
We are working to advance a deep pipeline of precision therapies, designed to allow patients to live longer, healthier lives. Our approach combines our leading expertise in protein kinases with sound execution and an intense focus on discovery.
We maintain a diverse and growing portfolio of research programs, moving multiple investigational medicines through clinical development for patients with a broad range of genomically defined cancers and rare diseases.
Over the past several decades our innovative medicines have improved how cancer is treated, making long-term survival a possibility for more patients. We strive to help more patients across a broad range of solid tumors and blood disorders with our medicines, scientific discovery and investigational research, and are working with partners to address all aspects of patient care, from diagnosis onward.
Bristol Myers Squibb
Daiichi Sankyo, Inc.
At Daiichi Sankyo, we create essential medicine for longer, better lives. By uniting cutting-edge science and technology with a genuine interest in people, we develop high-quality, life-changing solutions for the patients of today and tomorrow. We rely on reason, ingenuity, perseverance, and empathy to make bold strides in oncology.
We commit to a culture of equity and belonging that fuels exceptional value for our patients and business and unlocks the power of our people. It is the sum of our diverse perspectives, experiences and skills that informs our collective capability.
Our success comes from experts in collaboration: our people, scientists, health care providers, advocates – and patients themselves. Building on a 120-year heritage and a culture of innovation, we’re forging better futures through medicine for people everywhere. Together, we are creating new standards of care—our contribution to the enrichment of quality of life around the world.
Please visit www.daiichisankyo.us.
We are driven by a singular focus to bring life-enhancing cancer treatments to patients. Working across bi-coastal centers of discovery and development excellence, we are thinking bigger and broader than ever before to expand our product portfolio and propel oncology innovation forward.
We’re an essential partner to patients, physicians, researchers, and biopharma organizations navigating the complex landscape of cancer care. Our genomic insights help guide informed decisions about treatment plans and research priorities.
Over the past decade, we’ve partnered with researchers, biopharma, advocacy organizations, government bodies, health plans, and regulators to validate the use of genomic testing in clinical care, drive awareness among patients and physicians and ultimately support broader access for patients.
The answers we provide through our testing are essential first steps in developing informed treatment strategies and accelerating the development of transformative new therapies.
Genentech is a biotechnology company dedicated to pursuing groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases. Our transformational discoveries include the first targeted antibody for cancer and the first medicine for primary progressive multiple sclerosis.
For Activase prescribing information, click here:
Gilead Sciences, Inc.
At Gilead, we set – and achieve – bold ambitions to create a healthier world for all people. From our pioneering virology medicines to our growing impact in oncology, we're delivering innovations once thought impossible in medicine.
Our focus goes beyond medicines, and we also strive to remedy health inequities and break down barriers to care. We empower our people to tackle these challenges, and we’re all united in our commitment to help millions of people live healthier lives.
We are a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together.
We prioritize innovation in vaccines and specialty medicines to prevent and treat disease.
We at Janssen are entrusted with one of the most important jobs in the world. We aspire to transform lives by bringing life-saving and life-changing solutions to people who need them. We’re committed to providing safe and effective medicines as well as the services and support that contribute to healthy outcomes. This calls for the best science, the most creative minds and an openness to collaborate with researchers, governments and patient organizations at every stage – from early discovery to market access and patient education.
As a leading pharmaceutical company in the United States, we focus our innovation on some of the most devastating diseases and the most complex medical challenges of our time, across six therapeutic areas:
Cardiovascular & Metabolism
Infectious Diseases & Vaccines
Product Display - Zepzelca & Vyxeos
Johnson & Johnson Innovative Medicine
Patients inform and inspire our science-based innovations, which continue to change and save lives. Applying rigorous science and compassion, we confidently address some of the most complex diseases of our time and unlock the potential medicines of tomorrow.
Our diverse portfolio spans multiple therapeutic areas—Oncology, Immunology, Neuroscience, Cardiovascular, Pulmonary Hypertension, and Retina.
We are continuously working to develop treatments, aspiring to find cures, pioneering the path from lab to life, and championing patients every step of the way.
Founded in 2009 as a pioneer in cell therapy research, Kite’s leadership position in the immuno-oncology space was solidified with our research and development agreement with the National Cancer Institute in 2012 and when our commercial manufacturing site opened in El Segundo in 2016. Since our acquisition by biopharma leader Gilead Sciences in October 2017, our combined strength has accelerated the advancement of our pipeline, including the launch of YESCARTA® (axicabtagene ciloleucel) and TECARTUS® (brexucabtagene autoleucel), and has expanded the impact of our strategic partnerships.
As an independent operating company since 2019, we prioritize innovative R&D with the full resources, capabilities, and trust of Gilead. As a vital part of Gilead — a founding member of the Foundation for the NIH’s Partnership for Accelerating Cancer Therapies — we are devoted to advancing the understanding of cell therapy as a transformational treatment option for cancer. The combined strength of Kite and Gilead allows us to remain innovative, agile, and ambitious in our mission to keep improving the lives of people with all types of cancer.
Our purpose: We use the power of leading-edge science to save and improve lives around the world
For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world — and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities.
Mercy Health Ancillary Services
Mercy Health Cancer Centers
Mercy Health Rehabilitation Services
At Mirati, we convert possibility into reality by developing best-in-class targeted therapies to improve the lives of patients.
We’re in relentless pursuit of breakthroughs that change patients’ lives. We innovate every day to make the world a healthier place. It was Charles Pfizer’s vision at the beginning and it holds true today.
Pfizer Oncology strives to advance the frontiers of cancer biology and to translate this knowledge into high-impact medicines for cancer patients. Our core areas of interest include: Tumor Cell Biology; Precision Medicine; Tumor Targeted Therapeutics; Integrative Biotechnology; and Immuno- Oncology. In Tumor Cell Biology we are focused on oncogenic drivers, tumor metabolism, and epigenetics. Precision Medicine represents an integrated cluster of technology platforms and translational science configured to enable patient-tailored, hypothesis-driven experimental medicine approaches. Our Integrative Biotechnology Group supports novel target identification and validation through functional genomics, proteomics, and other “omic” approaches.
Pfizer, Rare Disease
Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The company was established in 1849 in New York by two German immigrants, Charles Pfizer and his cousin Charles F. Erhart.
Regeneron is a leading science-based biopharmaceutical company that invents, develops and commercializes medicines to treat serious medical conditions.
Seagen is a global biotechnology company dedicated to developing revolutionary therapies with real impact.
Taiho Oncology, Inc.
At Taiho Oncology our mission is to improve the lives of patients with cancer, their families, and their caregivers.
We’re building innovative tech solutions oriented around clinical care and research products—and the virtuous cycle between them.
Are you looking for exhibitor registration?
Sign Up to Exhibit
eeds Privacy and Registration Refund Policy
eeds Accessibility Statement